AI assistant
Ocugen, Inc. — Director's Dealing 2019
Dec 16, 2019
32915_dirs_2019-12-16_c809a9bf-9159-42f0-9d43-4f84dacfabfb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ocugen, Inc. (OCGN)
CIK: 0001372299
Period of Report: 2019-09-27
Reporting Person: JORGENSEN DANIEL (Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (right to buy) | $6.30 | 2027-04-17 | Common Stock (25888) | Direct | |
| Stock Options (right to buy) | $7.56 | 2027-12-15 | Common Stock (6712) | Direct | |
| Stock Options (right to buy) | $12.18 | 2028-08-23 | Common Stock (2397) | Direct | |
| Stock Options (right to buy) | $13.52 | 2028-12-07 | Common Stock (9588) | Direct |
Footnotes
F1: 17,258 Stock Options became exercisable immediately, and the remaining 8,630 Stock Options will become exercisable on April 16, 2020, subject to continued employment with Ocugen, Inc. (the "Company").
F2: 2,238 Stock Options became exercisable immediately, and the remaining 4,474 Stock Options will become exercisable on December 14, 2020, subject to continued employment with the Company.
F3: 799 Stock Options became exercisable immediately, and the remaining 1,598 Stock Options will become exercisable 50% each on July 23, 2020 and July 22, 2021, subject to continued employment with the Company through the applicable vesting date.
F4: The Stock Options will vest 1/3 each on December 7, 2019, December 7, 2020 and December 6, 2021, subject to continued employment with the Company through the applicable vesting date.